Early backer of breakthrough,
founder-led longevity companies
EXITED: IPO
First-in-class foundational checkpoint immunotherapies
NASDAQ: ALXO
Discovering new medicines with ultra-throughput biochemistry and machine learning
Next-generation interventions to cure neurodegeneration and delay brain aging
Targeting pathogenic cells to treat aging and chronic diseases
Turning stem cells into human eggs to reimagine family planning
EXITED: IPO
Regenerative and gene therapies to restore hearing and balance
NASDAQ: DBTX
Activation of the endogenous immune system for eliminating pathogenic cells
AI-led drug discovery engine translating conserved pathways of disease resistance across species
Next generation of induced proximity medicines
Pooled in vivo platform for new therapeutics tackling complex age-related disease
Healthspan and lifespan extension for dogs
EXITED: IPO
Therapies for gastrointestinal and liver disease
NASDAQ: MTCR
Platform for therapeutics targeting mTORC1
EXITED: IPO
Novel gene editing technology to develop new class of medicines
NASDAQ: DTIL
Therapeutics to heal the blood-brain barrier
Redefining human capabilities with advanced medical technology
Machine learning platform to accelerate drug discovery for aging
EXITED: IPO
Therapeutics to slow, halt, or reverse diseases of aging
NASDAQ: UBX
Stealth
Cryopreservation technology for tissues and organs to end organ supply shortages
Stealth
Developing therapies targeting gut-organ-axes to increase healthspan
Stealth
Multiplex-editing therapies to target age-related disease
Stealth
Precision therapeutics for genetic forms of neurodegeneration